Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in

Embla Medical hf
OTC:OSSUY

Watchlist Manager
Embla Medical hf Logo
Embla Medical hf
OTC:OSSUY
Watchlist
Price: 4.15 USD Market Closed
Market Cap: $1.8B
Write Note Create Alert Ask AI

Wall St Price Targets

OSSUY Price Targets Summary
Embla Medical hf

Wall Street analysts forecast OSSUY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OSSUY is 5.29 USD with a low forecast of 4.55 USD and a high forecast of 6.41 USD.

OSSUY Lowest Forecast
Wall Street Target
$4.55
10% Upside
OSSUY Average Forecast
Wall Street Target
$5.29
28% Upside
OSSUY Highest Forecast
Wall Street Target
$6.41
54% Upside
Lowest Forecast
Price Target
4.55 USD
10% Upside
Average Forecast
Price Target
5.29 USD
28% Upside
Highest Forecast
Price Target
6.41 USD
54% Upside
Embla Medical hf Competitors:
Price Targets

Revenue
Forecast

7% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
7% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 8%.

What are analyst estimates?

Gross Profit
Forecast

7% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
7% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 5 years is 9%.

What are analyst estimates?

Operating Income
Forecast

6% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
6% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 8 years is 11%.

What are analyst estimates?

Pre-Tax Income
Forecast

6% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
6% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 3 years is 16%.

What are analyst estimates?

Net Income
Forecast

6% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
6% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 5 years is 13%.

What are analyst estimates?

Continue OSSUY Research

Summary
OSSUY intrinsic value, competitors valuation, and company profile.
DCF Valuation
OSSUY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OSSUY stock valuation using valuation multiples.
Wall St Estimates
OSSUY price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OSSUY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Embla Medical hf listings:
OTC • USD
OSSFF
 LSE • DKK
0FIW
 CSE • DKK
EMBLA
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is OSSUY's stock price target?
Price Target
5.29 USD

According to Wall Street analysts, the average 1-year price target for OSSUY is 5.29 USD with a low forecast of 4.55 USD and a high forecast of 6.41 USD.

What is the Revenue forecast for Embla Medical hf?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 8%.

What is the Gross Profit forecast for Embla Medical hf?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 5 years is 9%.

What is the Operating Income forecast for Embla Medical hf?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 8 years is 11%.

What is the Pre-Tax Income forecast for Embla Medical hf?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 3 years is 16%.

What is the Net Income forecast for Embla Medical hf?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 5 years is 13%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.